Skip to Content


In the US, Stivarga (regorafenib systemic) is a member of the following drug classes: multikinase inhibitors, VEGF/VEGFR inhibitors and is used to treat Colorectal Cancer, Gastrointestinal Stromal Tumor and Hepatocellular Carcinoma.

US matches:

UK matches:

Ingredient matches for Stivarga


Regorafenib is reported as an ingredient of Stivarga in the following countries:

  • Austria
  • Bosnia & Herzegowina
  • Canada
  • Chile
  • Croatia (Hrvatska)
  • Denmark
  • Finland
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • Iceland
  • Ireland
  • Israel
  • Italy
  • Norway
  • Poland
  • Romania
  • Slovakia
  • Slovenia
  • Sweden
  • United Kingdom

Regorafenib monohydrate (a derivative of Regorafenib) is reported as an ingredient of Stivarga in the following countries:

  • Japan
  • Singapore
  • South Korea
  • Thailand
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.